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A Burkholderia pseudomallei type III secretion system real-time PCR assay was evaluated on clinical speci-
mens in a region where melioidosis is endemic. The PCR was positive in 30/33 (91%) patients with culture-
confirmed melioidosis. All six patients with melioidosis septic shock were blood PCR positive, suggesting
potential for rapid diagnosis and commencement of appropriate therapy.
Melioidosis is the disease caused by infection with the envi-
ronmental bacterium Burkholderia pseudomallei. In Southeast
Asia and northern Australia, melioidosis is an important cause
of community-acquired sepsis (1, 8). The clinical manifestations
of melioidosis vary widely in terms of time course, severity, and
organ system involvement, and it is difficult to differentiate
from other causes of sepsis. In its most severe form, melioido-
sis progresses rapidly to septic shock, end organ failure, and
death. The “gold standard” for diagnosis is culture from clin-
ical samples, but isolation and identification of B. pseudomallei
can take up to a week. Furthermore, B. pseudomallei is resis-
tant to many antibiotics used in the empirical treatment of
sepsis. A rapid diagnostic test would enable early therapy with
appropriate antibiotics, potentially decreasing the mortality
attributed to delayed therapy (8).
Serology is unreliable for early diagnosis due to both delayed
or absent seroconversion and high background seropositivity in
regions where melioidosis is endemic (2). Rapid immunofluo-
rescence microscopy of sputum has shown excellent specificity
but only 66% sensitivity (9). Various PCR tests for B. pseudo-
mallei have been developed, but most of them have only been
evaluated using pure bacterial cultures. Those evaluated on
clinical samples from patients with suspected melioidosis had
poor sensitivity and/or specificity (4, 5).
We initially evaluated a conventional PCR targeting a type
III secretion system gene cluster (TTS1). This PCR demon-
strated excellent specificity but was less sensitive than culture
(3). We have subsequently converted the PCR to a real-time
format (6), and we now report evaluation of the TTS1 real-
time PCR on specimens collected from patients presenting
with sepsis in an area where melioidosis is endemic.
Royal Darwin Hospital is a regional referral hospital located
in the tropical north of Australia, where melioidosis is en-
demic. The study was approved by the Human Research Ethics
Committee of the Department of Health and Community Ser-
vices and the Menzies School of Health Research. One hun-
dred seven patients who presented with possible melioidosis
had PCR performed on samples collected in parallel with those
sent for culture. These included blood cultures, sputum, urine,
pus, and other body fluids, as well as wound, throat, nose, and
rectal swabs. Melioidosis was confirmed in 33 patients by cul-
ture of B. pseudomallei from one or more samples.
DNA was extracted from the clinical samples as previously
described and was eluted in a volume of 200 l (3). Real-time
PCR was performed using the Rotor-Gene 2000 (Corbett Re-
search, Sydney, Australia). Samples were tested in duplicate
using in each reaction 4 l of template and a final reaction
volume of 25 l. The primers and fluorescent probe were as
previously described (6). The final concentrations of the re-
agents were 0.42 M each primer, 0.26 M probe, 1 U HotStar
Taq Polymerase (QIAGEN, Hilden, Germany), 0.2 mM de-
oxynucleotides, and 6.0 mM MgCl2. The cycling parameters
included an initial hold for 15 min at 95°C, 60 cycles of 15 s at
94°C and 60 s at 60°C, and a final hold for 2 min at 45°C. In
each run, B. pseudomallei-positive and no-template controls
were included.
Samples that were culture positive for B. pseudomallei and
not real-time PCR positive by this method were retested in
duplicate using a new protocol, which involved testing 23.5 l
template in a reaction volume of 50 l. Sixteen blood samples
from non-melioidosis patients were also tested in duplicate
using this method. The methods were as described above, with
the exceptions of MgCl2 being increased to 6.2 mM and the
denaturation time being increased to 30 s in each cycle.
Of the 33 patients with culture-confirmed melioidosis, 30
had one or more real-time PCR-positive samples, giving 91%
sensitivity for patient diagnosis. Four of 74 non-melioidosis
patients also had a real-time PCR-positive sample, giving spec-
ificity of 95%. These four patients all had respiratory infections
which responded to a short course of antibiotics. None re-
ceived specific melioidosis therapy or subsequently developed
confirmed melioidosis.
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Table 1 shows the culture and real-time PCR results of
individual samples collected from melioidosis patients. On
sputum, urine, drained pus, and wound swabs, the assay per-
formed with 100% sensitivity compared to culture. The sensi-
tivity of the assay on blood samples depended on the severity
of clinical disease. Fourteen of 19 (74%) culture-positive blood
samples from patients with septic shock were real-time PCR
positive using the 25-l reaction protocol, compared to 6 of 36
(17%) culture-positive blood samples from patients without
septic shock (P  0.001; Fisher exact test). All six patients with
melioidosis bacteremia with septic shock had at least one blood
PCR-positive result, compared with only 4/14 patients with
bacteremia without septic shock (P  0.005; Fisher exact test).
When the culture-positive, PCR-negative blood samples were
tested using the 50-l method, 11/35 were positive.
Table 2 shows the real-time PCR results for non-melioidosis
patient samples. Four of 205 samples were real-time PCR
positive. In addition, 1 of 16 blood samples from non-melioidosis
patients tested at the 50-l reaction volume was real-time PCR
positive. At no point were the no-template controls at either
reaction volume positive.
The TTS1 real-time PCR assay performed with 100% sen-
sitivity and specificity on sputum, urine, drained pus, and
wound swabs, with the high sensitivity reflecting the high bac-
terial load in samples from localized sites of infection. The
PCR was less sensitive on blood samples. However, for the
samples from those patients with melioidosis septic shock the
real-time PCR result was usually positive, and this is the pa-
tient cohort for whom a rapid diagnosis may be critical for
survival. Blood cultures involved four 10-ml samples, while
only 4 ml EDTA blood was collected for real-time PCR. Fur-
thermore, the DNA was only extracted from the buffy coat,
with only 4 l of the 200 l eluted DNA being tested in each
reaction. The increase in sensitivity associated with septic
shock and also with the 50-l method suggests small bacterial
numbers in negative samples. This is consistent with a previous
report that 45% of septicemic melioidosis patients have 1
CFU/ml in blood (7).
Sensitivity for blood samples could potentially be improved
by DNA extraction from a larger volume of sample and elution
in a smaller volume of buffer. Multiple PCR replicates could
also increase the likelihood of obtaining a positive result for
those samples with a DNA concentration at the lower limit of
detection. It is also possible that PCR inhibitors such as heme
and human DNA contribute to the lower sensitivity of blood
samples. A real-time PCR for diagnosing brucellosis was more
sensitive on serum than whole blood (10). On preliminary
further sampling of melioidosis patients, we have also found
pellets from centrifuged plasma to be more sensitive than the
TABLE 1. Samples from 33 culture-confirmed melioidosis patients
Sample type No. ofsamples
No. (%) of real-time PCR-positive
samples
25-l protocol 25-l and 50-lprotocolsa
Blood
Culture positive 55 20 (36) 31 (56)
Culture negative 23 4 (17)
Sputum
Culture positive 14 14 (100)
Culture negative 8 8 (100)
Throat swab
Culture positive 9 6 (66) 6 (66)
Culture negative 16 3 (19)
Rectal swab
Culture positive 5 2 (40) 2 (40)
Culture negative 17 1 (6)
Wound swab
Culture positive 10 10 (100)
Culture negative 1 0
Nose swab
Culture positive 2 2 (100)
Culture negative 2 1 (50)
Urine
Culture positive 5 5 (100)
Culture negative 11 8 (73)
Prostatic drainage fluid
Culture positive 5 5 (100)
Culture negative 0 0
Joint fluid
Culture positive 4 3 (75) 4 (100)
Culture negative 1 0
Pleural fluid
Culture positive 1 1 (100)
Culture negative 2 1 (50)
Pericardial fluid
Culture positive 0 0
Culture negative 1 1 (100)
Prostate tissue
Culture positive 1 1 (100)
Culture negative 0 0
Ankle tissue
Culture positive 1 1 (100)
Culture negative 0 0
a Samples which were culture positive but real-time PCR negative using the
25-l reaction protocol were tested using the 50-l method.
TABLE 2. Samples from 74 non-melioidosis patients
Sample type No. ofsamples
No. (%) of real-time
PCR-positive samples,
25-l protocol
Blood 58 0
Sputum 28 0
Throat swab 49 3 (6)
Rectal swab 47 1 (2)
Wound swab 5 0
Urine 3 0
Pleural fluid 2 0
Nose swab 7 0
Prostatic drainage 1 0
Drainage of bone collection 1 0
Pericardial fluid 1 0
Cerebrospinal fluid 1 0
Intervertebral disc aspirate 1 0
Pus 1 0
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buffy coat. For blood samples, we now elute DNA in 100 l
and test 8 l of template in a final reaction volume of 25 l.
Some culture-negative but real-time PCR-positive samples
were obtained from melioidosis patients. This probably usually
represents the detection of nonviable bacteria, as the majority
of these culture-negative but PCR-positive samples were taken
following commencement of specific melioidosis therapy. It is
unclear what the false-positive results from non-melioidosis
patients represent, but possibilities include contamination,
cross-reactivity with an alternative DNA sequence, detection
of undiagnosed melioidosis, or asymptomatic B. pseudomallei
carriage. The false-positive reactions were from swabs from
mucosal surfaces, and we currently recommend using this real-
time PCR only for blood, sputum, urine, cerebrospinal fluid,
and pus samples.
In summary, the TTS1 real-time PCR assay showed sensitive
and specific detection of B. pseudomallei DNA in samples from
localized sites of infection. Sensitivity in blood samples was
improved over our previous conventional PCR (3), and the
assay has the potential to make a rapid diagnosis in patients
with melioidosis septic shock. Further evaluation is required in
other locations where melioidosis is endemic, with testing of
samples from multiple tissue sites in parallel with culture.
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